Previous 10 | Next 10 |
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that CEO Adelene Perkins is scheduled to present virtually at three investor conferences this month. The Infinity leadership team also will be available for one-on-one meetings during the investor conferences on January 7...
Infinity Pharmaceuticals ([[INFI]] +4.8%) has provided an update on MARIO-275 Phase 2 study evaluating the benefit of adding eganelisib to Bristol-Myers' Opdivo (nivolumab) in platinum-refractory advanced urothelial cancer patients who are immuno-oncology therapy-naïve, over nivolum...
-Infinity Planning New, Registration-Enabling Study in Advanced Urothelial Cancer Leveraging Encouraging Data from MARIO-275- -MARIO-275 Data to be Presented at a Major Medical Meeting in Q1 2021- -Infinity Provides 2021 Milestones and Financial Guidance- I...
Oncternal Therapeutics (ONCT) -25% on increasing previously announced bought deal offer to $75.0M.GeoVax Labs (GOVX) -23%.Xenetic Biosciences (XBIO) -21%. on launching $6M registered direct offering priced at-the-market.Savara (SVRA) -19% on providing pipeline and business...
The following slide deck was published by Infinity Pharmaceuticals, Inc. in conjunction with this event. For further details see: Infinity Pharmaceutical (INFI) Presents at San Antonio Breast Cancer Symposium - Slideshow
Gainers: Greenwich LifeSciences (GLSI) +424%.Xenetic Biosciences (XBIO) +329%.Rocket Pharmaceuticals (RCKT) +79%.MTS Systems (MTSC) +52%.Cypress Environmental Partners (CELP) +46%.Intec Pharma (NTEC) +42%.ZW Data Action Technologies (CNET) +33%.Cardtronics (CATM) +33%.Editas Medicine (ED...
Infinity Pharmaceuticals ([[INFI]] -19.5%) has announced data from the front-line triple negative breast cancer cohort from its ongoing MARIO-3 trial, evaluating eganelisib in combination with atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane). Data were presented at the Sa...
Gainers: Xenetic Biosciences (XBIO) +410%, Greenwich LifeSciences (GLSI) +289%, Rocket Pharmaceuticals (RCKT) +74%, Intec Pharma (NTEC) +64%, ViewRay (VRAY) +14%.Losers: Atossa Therapeutics (ATOS) -39%, Pluristem Therapeutics (PSTI)&...
- 100% of Evaluable Patients Achieved Tumor Reduction Irrespective of PD-L1 Status - - 69.2% of Evaluable Patients Achieved Best Responses of Complete Response or Partial Response - - Safety Consistent With Expectations Of Component Drugs - - Conference...
Gainers: Curis (CRIS) +335%.Lexicon Pharmaceuticals (LXRX) +97%.Mammoth Energy Services (TUSK) +61%.NeuroMetrix (NURO) +49%.Stitch Fix (SFIX) +45%.IGM Biosciences (IGMS) +38%.Blonder Tongue Laboratories (BDR) +26%.Infinity Pharmaceuticals (INFI) +25%.KLX Energy Services (KLXE) +24%....
News, Short Squeeze, Breakout and More Instantly...
Infinity Pharmaceuticals Inc. Company Name:
INFI Stock Symbol:
NASDAQ Market:
Infinity Pharmaceuticals Inc. Website:
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - Infinitum Copper Corp. (TSXV: INFI) (OTCQB: INUMF) (" Infinitum " or the " Company ") is pleased to announce that it has received acceptance from the TSX Venture Exchange (the " Exchange ") of the previously announced consolidation ...
VANCOUVER, BC / ACCESSWIRE / April 3, 2024 / Infinitum Copper Corp. (TSXV:INFI, OTCQB:INUMF) (" Infinitum " or the " Company ") is pleased to announce the details of a proposed consolidation of its common shares. On March 21, 2024, in accordance with the constating documents of the Company, the ...
VANCOUVER, BC / ACCESSWIRE / March 6, 2024 / Infinitum Copper Corp. (TSXV:INFI)(OTCQB:INUMF) (" Infinitum " or the " Company "). Further to the Company's news release of March 5, 2024 (the " March 5, 2024 News Release "), this is to advise that the Company has amended the terms of its private pl...